The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations

,

doi:10.1002/mds.10473

Cited by 1,472 publications

(447 citation statements)

References 52 publications

Supporting

Mentioning

440

Contrasting

Unclassified

Order By: Relevance

“…RBD subjects and controls were investigated with the Unified Parkinson's Disease Rating Scale (UPDRS, version 200323) and the Montreal Cognitive Assessment (MoCA) 24. Olfactory function was assessed with Sniffin' Sticks 15, 16, 25.…”

Section: Methodsmentioning

confidence: 99%

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

et al. 2017

View full text Add to dashboard Cite

BackgroundIdiopathic REM sleep behavior disorder is a prodromal stage of Parkinson's disease and dementia with Lewy bodies. Hyposmia, reduced dopamine transporter binding, and expression of the brain metabolic PD‐related pattern were each associated with increased risk of conversion to PD. The objective of this study was to study the relationship between the PD‐related pattern, dopamine transporter binding, and olfaction in idiopathic REM sleep behavior disorder.MethodsIn this cross‐sectional study, 21 idiopathic REM sleep behavior disorder subjects underwent 18F‐fluorodeoxyglucose PET, dopamine transporter imaging, and olfactory testing. For reference, we included 18F‐fluorodeoxyglucose PET data of 19 controls, 20 PD patients, and 22 patients with dementia with Lewy bodies. PD‐related pattern expression z‐scores were computed from all PET scans.ResultsPD‐related pattern expression was higher in idiopathic REM sleep behavior disorder subjects compared with controls (P = 0.048), but lower compared with PD (P = 0.001) and dementia with Lewy bodies (P < 0.0001). PD‐related pattern expression was higher in idiopathic REM sleep behavior disorder subjects with hyposmia and in subjects with an abnormal dopamine transporter scan (P < 0.05, uncorrected).ConclusionPD‐related pattern expression, dopamine transporter binding, and olfaction may provide complementary information for predicting phenoconversion. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

show abstract

Section: Methodsmentioning

confidence: 99%

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

et al. 2017

View full text Add to dashboard Cite

show abstract

“…(1) Unified Parkinson's disease rating score (UPDRS) 7 : The UPDRS consists of 42 items which are grouped in four sections: subscale I -mentation, behavior, and mood section; subscale II -activities of daily living; subscale III -motor examination; subscale IV -complications of therapy. Higher scores reflect higher severity;…”

Section: Subjectsmentioning

confidence: 99%

Clinical predictors of cognitive impairment and psychiatric complications in Parkinson’s disease

Campos

Guimarães

Piovesana

et al. 2015

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Parkinson disease (PD) is characterized by a combination of motor and non-motor symptoms (NMS). While the motor symptoms are well defined, the NMS could be underestimated. The prevalence of NMS after 7 years of disease duration is around 90% 1 and several studies showed that NMS, such as psychiatric disorders and cognitive impairment could be potentially exacerbated by the treatment.The prevalence rate of PD has been estimated in 3.3% in the Brazilian population 2 . Cognitive impairment is a common NMS in PD patients, and increasing age, older age at onset of disease, longer disease duration, severity of parkinsonism, male gender, higher doses of antiparkinsonian drugs and the presence of psychiatric symptoms have been linked to increased risk of developing dementia 2,3 . Despite the high impact in quality of life of PD patients 4 the incidence and prevalence rates of cognitive impairment and psychiatric symptoms in Brazilian PD patients are scarce 5 .Therefore we evaluated the demographic and clinical characteristics of a cohort of Brazilian PD patients, using validated scales to assess the motor symptoms and NMS. Our goal was ABSTRACTObjective: To estimate the clinical and demographics aspects that may contribute to cognitive impairment and psychiatric symptoms in Parkinson's disease (PD). Method: All patients answered a structured standardized clinical questionnaire. Two movement disorders specialists performed the following scale: Unified Parkinson's disease rating score (UPDRS), the modified Hoehn and Yahr staging, Schwab and England Scale, SCOPA cognition (SCOPA-COG), SCOPA-Psychiatric complications (SCOPA-PC) and Non-Motor Symptoms Scale (NMSS). We built a generalized linear model to assess predictors for the SCOPA-COG and SCOPA-PC scores. Results: Almost 37% of our patients were demented as per SCOPA-COG scores. Level of education and the UPDRS-Subscale III were predictors of cognitive impairment. Higher scores in domain 3 of NMSS and male gender were associated with psychiatric complications as assessed per the SCOPA-PC. Conclusion: Level of education and disease severity are predictors of dementia in PD. Psychiatric complications are more commonly observed in men.Keywords: Parkinson, cognition, psychiatric status rating scales, dementia, risk factors. RESUMOObjetivo: Estimar aspectos clínicos e demográficos que podem contribuir para o comprometimento cognitivo e sintomas psiquiátricos na doença de Parkinson (DP). Método: Todos pacientes responderam questionário clínico padrão. Duas especialistas em distúrbios do movimento aplicaram as seguintes escalas: Unified Parkinson's disease rating score (UPDRS), Hoehn and Yahr estágios, Schwab and England Scale, SCOPA cognição (SCOPA-COG), SCOPA-Complicações psiquiátricas (SCOPA-CP) e Escala de sintomas não motores (NMSS). Utilizamos análise multivariada, para avaliar os preditores relacionados ao SCOPA-COG e SCOPA CP. Resultados: Aproximadamente 37% dos nossos pacientes foram classificados como dementes utilizando-se os valores obtidos no SCOPA-COG. Nível educ...

show abstract

“…The Unified Parkinson’s Disease Rating Scale has proven to be reliable and valid [34], and it is the most widely used rating scale for measuring severity of parkinsonian symptoms in clinical research and practice [35]. It includes a patient- or caregiver-provided estimate of dyskinesia duration during the waking day (0, 1–25, 26–50, 51–75 or 76–100%) for the past week and a rating of its severity (not disabling, mildly disabling, moderately disabling, severely disabling or completely disabling) [36].…”

Section: Impact Of Dyskinesias On Quality Of Lifementioning

confidence: 99%

Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

Encarnacion¹,

Hauser

2008

Eur Neurol

View full text Add to dashboard Cite

Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson’s disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation.

show abstract

The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations

Cited by 1,472 publications

References 52 publications

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder

Clinical predictors of cognitive impairment and psychiatric complications in Parkinson’s disease

Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

Contact Info

Product

Resources

About